EXTON, Pa., Jan. 6, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that Cindy Reiss-Clark, Sr. VP and Chief Commercial Officer; Chad Winters, VP of Finance and Chief Accounting Officer; and John Sweeney, VP of Investor Relations, will present at the CJS 25th Annual "New Ideas for the New Year" Virtual Investor Conference on January 14, 2025 at 10:15 a.m. ET.  A live audio webcast will be availab ...

Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estim ...

EXTON, Pa., Dec. 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the Company's Board of Directors has elected Janet Haugen as its newest member. With the addition of Ms. Haugen, West's Board has 12 directors. Janet Haugen Ms. Haugen, 66, is the former Chief Financial Officer of Unisys Corporation, a role she served in for more than 16 years. During her 20-year tenure at Unisys, Ms. Hauge ...

West Pharmaceutical Services, Inc. (WST) is well poised for growth, backed by the robust Proprietary Products segment and sustained strength in research and development (R&D). However, foreign exchange volatility is a concern.Shares of this Zacks Rank #3 (Hold) company have lost 12.8% year to date against the industry's 2.8% growth. The S&P 500 Index has increased 23.4% in the same time frame.West Pharmaceutical, with a market capitalization of $22.78 billion, is a leading global manufacturer, engaged in th ...

EXTON, Pa., Oct. 29, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following conferences: UBS Global Healthcare Conference in Rancho Pablos Verdes, California, on November 12, 2024 at 3:30 PM PST Jefferies Healthcare Conference in London, UK on Tuesday, November 19, 2024 at 1:00 PM GMT Stephens Annual Investment Conference in Nashville, TN on Thursday, November 21, 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State ...

财务数据和关键指标变化 - 第三季度净销售额为746.9百万美元，较去年同期有0.5%的有机销售下降 [11] - 调整后的每股收益（EPS）较去年同期下降14.4% [12] - 调整后的运营利润率为21.5%，较去年同期下降270个基点 [12][14] 各条业务线数据和关键指标变化 - 专有产品的有机净销售额下降0.5%，高价值产品占专有产品销售的约75% [11] - 制药市场单位销售中位数增长，生物制药市场单位销售小幅下降，主要受FluroTec、NovaPure和Westar产品去库存影响 [12] - 合同制造部门的收入在恒定汇率下与去年同期持平 [12] 各个市场数据和关键指标变化 - 制药市场单位销售中位数增长，生物制药市场单位销售小幅下降，仿制药市场单位销售下降中位数 [12] - 预计生物制药市场在第四季度将有所改善，主要受可穿戴自注射设备的推动 [7][10] 公司战略和发展方向和行业竞争 - 公司在生物制药领域保持强劲地位，计划继续投资于高增长领域以提升执行力和利润率 [7][9] - 公司正在扩大高价值产品和合同制造能力，以应对新机会 [9][15] - 计划通过优化制造流程和自动化来提高利润率 [9] 管理层对经营环境和未来前景的评论 - 管理层对未来前景持乐观态度，认为市场需求将逐步正常化 [10][25] - 预计2024年将继续面临去库存的挑战，但对生物制药市场的改善持积极看法 [10][25] 其他重要信息 - 公司在第三季度的运营现金流为463.3百万美元，较去年同期下降13.8% [15] - 资本支出为272.1百万美元，较去年同期增加 [15] 问答环节所有提问和回答 问题: 有机增长指导的变化 - 管理层表示，第三季度的强劲表现主要是由于客户去库存速度放缓和需求的加速 [20] 问题: 边际利润恢复的可见性 - 管理层认为，边际利润的恢复取决于需求的正常化和产品组合的调整 [21] 问题: 合同制造的毛利率变化 - 管理层预计合同制造的毛利率将在未来12到24个月内略有上升，主要受药物处理业务的推动 [45] 问题: GLP-1市场的机会 - 管理层表示，GLP-1市场的增长将依赖于最终患者的消费，且公司在该领域的参与度很高 [48] 问题: 客户订单行为的变化 - 管理层指出，当前的订单模式更接近于疫情前的状态，客户对交货时间的信心有所恢复 [59]

业绩总结 - 2024年第三季度净销售额为7.469亿美元，同比下降0.1%[8] - 报告的稀释每股收益为1.85美元，较去年同期的2.14美元下降[11] - 第三季度毛利率为35.4%，较去年同期的38.6%下降[11] - 报告的营业利润为1.613亿美元，较去年同期的1.773亿美元下降[11] - 2024年截至9月30日，公司的营业利润为410.3百万美元，净收入为362.6百万美元，稀释每股收益为4.91美元[27] - 2024年第三季度报告的净销售额为746.9百万美元，其中专有产品销售为601.4百万美元，CM销售为145.5百万美元[33] 用户数据 - 2024年截至9月30日，公司的有机净销售额为744.0百万美元，较2023年同期的2217.8百万美元有所下降[34] - 2024年前九个月，基于股票补偿的税收利益使调整后稀释每股收益增加了0.26美元[38] - 2023年基于股票补偿的税收利益使调整后稀释每股收益增加了0.42美元[38] 未来展望 - 2024年全年的净销售额指导范围为28.75亿至29.05亿美元[20] - 2024年调整后的稀释每股收益指导范围为6.55至6.75美元[20] - 2024年预计稀释每股收益（U.S. GAAP）为6.52至6.72美元，较2023年的7.88美元下降17.3%至14.7%[37] - 2024年截至9月30日，公司的调整后稀释每股收益（Non-U.S. GAAP）为6.55至6.75美元，较2023年的8.08美元下降18.9%至16.5%[37] 财务状况 - 2024年第三季度的自由现金流为1.912亿美元，较去年同期的2.841亿美元下降[18] - 2024年第三季度的总资产为4.909亿美元，较2023年12月31日的8.539亿美元下降[18] - 2024年第三季度的资本支出为2.721亿美元，较去年同期的2.533亿美元上升[18] - 2024年截至9月30日，公司的调整后营业利润为410.0百万美元，调整后净收入为364.1百万美元[27] - 2023年第三季度的调整后营业利润为180.8百万美元，调整后净收入为162.4百万美元[30] 其他信息 - 2024年第三季度的生物制药产品有机销售额因高价值产品的去库存而下降[13]

On Thursday, West Pharmaceutical Services, Inc. WST reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50.The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $746.9 million, beating the consensus of $709.62 million.The Proprietary Products Segment’s sales declined by 0.2% to $601.4 million, and the organic net sales decline was 0.5%.High-value products (components and devices) represented over 75% of segment net sal ...

West Pharmaceutical Services, Inc. (WST) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.85, which beat the Zacks Consensus Estimate of $1.51 by 22.5%. However, the bottom line decreased 14.4% year over year.The adjustments include expenses related to the amortization of acquisition-related intangible assets.GAAP EPS for the quarter was $1.85, down 13.6% year over year.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Revenues in DetailWest Pharmaceutical registere ...